SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-196966
Filing Date
2022-07-19
Accepted
2022-07-19 16:06:00
Documents
12
Period of Report
2022-07-18
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d379025d8k.htm   iXBRL 8-K 26225
  Complete submission text file 0001193125-22-196966.txt   151268

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20220718.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20220718_lab.xml EX-101.LAB 18759
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20220718_pre.xml EX-101.PRE 11708
6 EXTRACTED XBRL INSTANCE DOCUMENT d379025d8k_htm.xml XML 3472
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 221091629
SIC: 2834 Pharmaceutical Preparations